60 Degrees Pharmaceuticals Inc
Officers & Directors
Geoffrey Dow, age 52, has served as Chief Executive Officer, President, and Director since June 1, 2022. He has over 20 years of experience in product development for tropical diseases, including 13 years in leadership positions at the Walter Reed Army Institute of Research and the U.S. Army Medical Materiel Development Activity. He co-founded 60 P in 2010 and has led projects involving FDA approval for Tafenoquine (Arakoda) and related regulatory and patent matters. He holds a B.Sc. (Hons) and Ph.D. in Veterinary and Biomedical Science from Murdoch University and an MBA from the University of Maryland.
Tyrone Miller, age 51, is the Chief Financial Officer. He joined 60 P in 2014 and has held roles including Treasurer. He has raised over $6 million in financing. Miller is the founder and Principal of Miller Tax & Advisory since 2011 and is a Certified Public Accountant. He holds a Bachelor's degree in Business Administration from Emory University.
Kristen Landon, age 59, is the Chief Commercial Officer, joining the company in 2024. She has over 26 years of pharmaceutical brand experience, having launched more than a dozen brands with revenues exceeding $100 million. Her previous senior marketing roles include positions at TherapeuticsMD, Radius Health, Sprout Pharmaceuticals, Actavis Plc, Forest Labs, Abbott Labs, and Novartis. She holds an MBA from Silberman College of Business at Fairleigh Dickinson University and a Bachelor's degree from Kean University.
Charles Allen, age 50, has been a Director since July 11, 2023, and has served as Chief Executive since February 5, 2014.
60 Degrees Pharmaceuticals Inc currently has 3 employees.
News about 60 Degrees Pharmaceuticals Inc Key Personnel |
Introduction
In a significant development for 60 Degrees Pharmaceuticals (60P), the United States Food and Drug Administration (FDA) has communicated its intention to respond to the company s trial protocol submission for tafenoquine in the treatment of babesiosis. The response, originally expected in March 2024, is now anticipated by the end of April 2024. Despite the slight delay, 60P remains optimistic and is actively preparing for the trial s commencement on June 1, 2024. This update highlights the importance of this breakthrough antimalarial drug and the potential benefits it could bring in the management of babesiosis.
Background
Babesiosis is a tick-borne parasitic infection caused ...
|
In a move aimed at advancing their mission of combating malaria and further expanding their research endeavors, 60 Degrees Pharmaceuticals (60P) has announced a public offering pricing of $2.4 million. The funds generated from this offering will be utilized for various purposes including working capital, the relaunch of their flagship product ARAKODA for malaria prevention, and further research initiatives.
Malaria, a life-threatening disease caused by parasites transmitted through mosquito bites, continues to be a major global health concern, particularly in developing countries. The World Health Organization estimates that in 2019 alone, there were about 229 million malaria cases worldwide, result...
|
|
